BYOMass is a preclinical pharmaceutical company focused on developing innovative biologic and small molecule drugs to modulate specific members of the TGF-β superfamily. By targeting the causative mechanisms of diseases, BYOMass aims to address both rare and common conditions with high unmet medical needs. Driven by a mission to harness human biology and deliver transformative therapeutics, the company is committed to advancing ground-breaking treatments that improve patient outcomes and quality of life.